| Symbol | KRYS |
|---|---|
| Name | KRYSTAL BIOTECH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2100 WHARTON STREET,SUITE 701, PITTSBURGH, Pennsylvania, 15203, United States |
| Telephone | +1 412 586-5830 |
| Fax | — |
| — | |
| Website | https://www.krystalbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001711279 |
| Description | Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Additional info from NASDAQ: |
(90% Positive) KRYSTAL BIOTECH, INC. (KRYS) Announces Enrollment Update for revenue Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreKrystal Biotech Announces First Quarter 2026 Financial and Operating Results
Read moreNew Form SCHEDULE 13G/A - Krystal Biotech, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001298709-26-000007 <b>Size:</b> 176 KB
Read moreNew Form SCHEDULE 13G - Krystal Biotech, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0002100121-26-000495 <b>Size:</b> 7 KB
Read moreKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Read moreNew Form DEFA14A - Krystal Biotech, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001711279-26-000037 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Krystal Biotech, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001711279-26-000036 <b>Size:</b> 3 MB
Read moreNew Form SCHEDULE 13G/A - Krystal Biotech, Inc. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0000102909-26-001667 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07127913 | Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression | Na | Bipolar II Disorder | Recruiting | 2025-07-16 | 2035-06-28 | ClinicalTrials.gov |
| NCT06999733 | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophi… | Phase1 | Neurotrophic Keratitis | Recruiting | 2025-07-07 | 2027-12-01 | ClinicalTrials.gov |
| NCT07016750 | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epiderm… | Phase3 | Dystrophic Epidermolysis Bullosa | Recruiting | 2025-06-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06724900 | A Study Assessing KB304 for the Treatment of Wrinkles in Women | Phase1 | Wrinkles in Decolletage | Active_Not_Recruiting | 2024-11-20 | 2025-08-01 | ClinicalTrials.gov |
| NCT06563414 | A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epider… | — | Epidermolysis Bullosa Dystrophica | Recruiting | 2024-08-02 | 2025-12-01 | ClinicalTrials.gov |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies … | Phase1 | Lung Cancer, Non-small Cell | Recruiting | 2024-04-17 | 2028-07-01 | ClinicalTrials.gov |
| NCT06049082 | A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Phase1 | Alpha 1-Antitrypsin Deficiency | Recruiting | 2024-02-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Sol… | Phase1 | Cancer | Recruiting | 2023-10-31 | 2027-07-01 | ClinicalTrials.gov |
| NCT05504837 | A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Phase1 | Cystic Fibrosis | Recruiting | 2023-06-30 | 2027-03-01 | ClinicalTrials.gov |
| NCT05735158 | Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenita… | Phase2 | Autosomal Recessive Ichthyosis | Unknown | 2023-03-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT05095246 | A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis | Phase1 | Cystic Fibrosis | Withdrawn | 2022-03-08 | 2024-10-30 | ClinicalTrials.gov |
| NCT04917887 | Long-Term Follow-up Protocol | — | Dystrophic Epidermolysis Bullosa | Recruiting | 2021-05-25 | 2028-05-25 | ClinicalTrials.gov |
| NCT04917874 | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Phase3 | Dystrophic Epidermolysis Bullosa | Completed | 2021-05-25 | 2023-07-31 | ClinicalTrials.gov |
| NCT04540900 | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Exp… | Phase1 | Skin Roughness | Active_Not_Recruiting | 2020-10-07 | 2029-05-31 | ClinicalTrials.gov |
| NCT04491604 | Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB | Phase3 | Dystrophic Epidermolysis Bullosa | Completed | 2020-08-17 | 2022-01-14 | ClinicalTrials.gov |
| NCT04214002 | The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa… | — | Dystrophic Epidermolysis Bullosa | Withdrawn | 2020-01-01 | 2020-02-24 | ClinicalTrials.gov |
| NCT04047732 | Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recess… | Phase1 | TGM-1 Related Autosomal Recessive Congenital Ichthyosis | Unknown | 2019-08-27 | 2025-03-01 | ClinicalTrials.gov |
| NCT03536143 | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients | Phase1 | Dystrophic Epidermolysis Bullosa | Completed | 2018-05-06 | 2019-11-01 | ClinicalTrials.gov |
| NCT03217110 | Cerebellar Stimulation and Cognitive Control | Na | Schizophrenia | Recruiting | 2017-11-30 | 2028-12-01 | ClinicalTrials.gov |
| NCT02218775 | FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid … | Phase1 | Anxiety Disorders | Withdrawn | 2014-10-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | Phase1 | Pilomyxoid Astrocytoma | Completed | 2013-10-22 | 2024-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| LY2456302 | Other | Phase PHASE1 | Anxiety Disorders | WITHDRAWN | NCT02218775 |
| LY2456302 | Other | Phase PHASE1 | Anxiety Disorders | WITHDRAWN | NCT02218775 |
| KB105 | Other | Phase PHASE1 | TGM-1 Related Autosomal Recessive Congenital Ichthyosis | UNKNOWN | NCT04047732 |
| Placebo gel | Other | Phase PHASE1 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT03536143 |
| Topical beremagene geperpavec | Other | Phase PHASE1 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT03536143 |
| Placebo | Other | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT04491604 |
| Topical Beremagene Geperpavec | Other | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT04491604 |
| Placebo | Other | Phase PHASE2 | Autosomal Recessive Ichthyosis | UNKNOWN | NCT05735158 |
| KB105 | Other | Phase PHASE2 | Autosomal Recessive Ichthyosis | UNKNOWN | NCT05735158 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | WITHDRAWN | NCT05095246 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Other | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT04917874 |
| Irinotecan | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Bevacizumab | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Temozolomide | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Carboplatin | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Vincristine | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Mebendazole | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Irinotecan | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Bevacizumab | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Temozolomide | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Carboplatin | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Vincristine | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| Mebendazole | Other | Phase PHASE1 | Pilomyxoid Astrocytoma | COMPLETED | NCT01837862 |
| 0.9% Normal Saline (NS) | Other | Phase PHASE1 | Wrinkles in Decolletage | ACTIVE_NOT_RECRUITING | NCT06724900 |
| KB304 | Other | Phase PHASE1 | Wrinkles in Decolletage | ACTIVE_NOT_RECRUITING | NCT06724900 |
| Placebo | Other | Phase PHASE1 | Skin Roughness | ACTIVE_NOT_RECRUITING | NCT04540900 |
| KB301 | Other | Phase PHASE1 | Skin Roughness | ACTIVE_NOT_RECRUITING | NCT04540900 |
| KEYTRUDA ®( Pembrolizumab) | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05970497 |
| Opdualag | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05970497 |
| KB707 | Other | Phase PHASE1 | Cancer | RECRUITING | NCT05970497 |
| KB408 (Nebulization) | Other | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT06049082 |
| Device: Stimulation -ON Active Control | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| Device: Stimulation-OFF | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| Device: Stimulation-ON | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| Device: Stimulation -ON Active Control | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| Device: Stimulation-OFF | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| Device: Stimulation-ON | Device | Approved | Bipolar II Disorder | RECRUITING | NCT07127913 |
| KB407 (Nebulization) | Other | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| Placebo | Other | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | RECRUITING | NCT07016750 |
| KB803 | Other | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | RECRUITING | NCT07016750 |
| Docetaxel | Other | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| Chemotherapy | Drug | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| KB707 | Other | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| Placebo | Other | Phase PHASE1 | Neurotrophic Keratitis | RECRUITING | NCT06999733 |
| KB801 | Other | Phase PHASE1 | Neurotrophic Keratitis | RECRUITING | NCT06999733 |
| Sham Repetitive Transcranial Magnetic Stimulation (rTMS) | Other | Approved | Schizophrenia | RECRUITING | NCT03217110 |
| Repetitive Transcranial Magnetic Stimulation (rTMS) | Other | Approved | Schizophrenia | RECRUITING | NCT03217110 |
| Sham Repetitive Transcranial Magnetic Stimulation (rTMS) | Other | Approved | Schizophrenia | RECRUITING | NCT03217110 |
| Repetitive Transcranial Magnetic Stimulation (rTMS) | Other | Approved | Schizophrenia | RECRUITING | NCT03217110 |
| KB803 | BIOLOGICAL | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | RECRUITING | NCT07016750 |
| KB801 | BIOLOGICAL | Phase PHASE1 | Neurotrophic Keratitis | RECRUITING | NCT06999733 |
| 0.9% Normal Saline (NS) | DRUG | Phase PHASE1 | Wrinkles in Decolletage | ACTIVE_NOT_RECRUITING | NCT06724900 |
| KB304 | BIOLOGICAL | Phase PHASE1 | Wrinkles in Decolletage | ACTIVE_NOT_RECRUITING | NCT06724900 |
| Docetaxel | DRUG | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| Chemotherapy | DRUG | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| Pembrolizumab (KEYTRUDA®) | DRUG | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| KB408 (Nebulization) | DRUG | Phase PHASE1 | Alpha 1-Antitrypsin Deficiency | RECRUITING | NCT06049082 |
| KEYTRUDA ®( Pembrolizumab) | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05970497 |
| Opdualag | DRUG | Phase PHASE1 | Cancer | RECRUITING | NCT05970497 |
| KB707 | BIOLOGICAL | Phase PHASE1 | Lung Cancer, Non-small Cell | RECRUITING | NCT06228326 |
| KB407 (Nebulization) | BIOLOGICAL | Phase PHASE1 | Cystic Fibrosis | RECRUITING | NCT05504837 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | BIOLOGICAL | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT04917874 |
| KB301 | BIOLOGICAL | Phase PHASE1 | Skin Roughness | ACTIVE_NOT_RECRUITING | NCT04540900 |
| Placebo | DRUG | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | RECRUITING | NCT07016750 |
| Topical Beremagene Geperpavec | BIOLOGICAL | Phase PHASE3 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT04491604 |
| KB105 | BIOLOGICAL | Phase PHASE2 | Autosomal Recessive Ichthyosis | UNKNOWN | NCT05735158 |
| Placebo gel | BIOLOGICAL | Phase PHASE1 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT03536143 |
| Topical beremagene geperpavec | BIOLOGICAL | Phase PHASE1 | Dystrophic Epidermolysis Bullosa | COMPLETED | NCT03536143 |